Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 9/20 | 0.40 |
| ▸ | KIT | P10721 | 3/20 | 0.40 |
| ▸ | MARK3 | P27448 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.37 |
| ▸ | HAT1 | O14929 | 3/20 | 0.36 |
| ▸ | EP300 | Q09472 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2291527 | 0.89 | MAPK1 (0.49) | MAPK1KITHAT1EP300 | |
| SCHEMBL2289548 | 0.87 | KIT (0.48) | MAPK1KIT | |
| SCHEMBL15104463 | 0.87 | KIT (0.48) | MAPK1KIT | |
| SCHEMBL2289553 | 0.87 | MAPK1 (0.51) | RETMAPK1KIT | |
| SCHEMBL2292119 | 0.85 | MAPK1 (0.52) | MAPK1 | |
| SCHEMBL2355613 | 0.85 | MAPK1 (0.52) | MAPK1 | |
| SCHEMBL12379625 | 0.84 | MAPK1 (0.43) | RETMAPK1KITMARK3 | |
| SCHEMBL2290601 | 0.84 | MAPK1 (0.45) | MAPK1KITHAT1EP300 | |
| SCHEMBL2289980 | 0.84 | MAPK1 (0.54) | RETMAPK1KITMARK3 | |
| SCHEMBL15104469 | 0.84 | MAPK1 (0.54) | RETMAPK1KITMARK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518911-B2 | Pyrazolo[1,5-a]pyridines as MARK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | claimed |
| EP-2320737-B1 | PYRAZOLO-[1,5-A]-PYRIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME (US) | 2013-07-17 | — | — | EP | claimed |
| US-20110195933-A1 | PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-11 | — | — | US | claimed |
| US-8518911-B2 | Pyrazolo[1,5-a]pyridines as MARK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518911-B2 | Pyrazolo[1,5-a]pyridines as MARK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518911-B2 | Pyrazolo[1,5-a]pyridines as MARK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2320737-B1 | PYRAZOLO-[1,5-A]-PYRIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME (US) | 2013-07-17 | — | — | EP | disclosed |
| EP-2320737-B1 | PYRAZOLO-[1,5-A]-PYRIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20110195933-A1 | PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110195933-A1 | PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110195933-A1 | PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195933-A1 | PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS | MARK3, MARK4, MARK1 | RET 1650/4885MAPK1 60/4885KIT 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.